Dr. Panteli Theocharous

Dr. Panteli Theocharous is a seasoned leader with over 35-years of experience driving groundbreaking translational research, clinical development, and commercial strategy in the healthcare sector. With an established focus on Haematology/Oncology, Cell and Gene Therapy, Dr. Theocharous has led the development and market introduction of multiple transformative cancer therapies, contributing significantly to advancements in Patient care. His extensive career includes roles in several private and public Biotech companies, and in prominent organisations such as Janssen Oncology and PPD (now part of Thermo Fisher Scientific), where he was instrumental in fostering a culture of innovation, building high-performing global teams, and delivering impactful therapeutic solutions.

Trained as a Clinical Immunologist at the Royal Free Hospital in London, Dr. Theocharous specialised in haematopoietic stem cell transplantation, cell and gene therapies, gaining early expertise in the translational applications of cutting-edge scientific research. His work extends across asset lifecycle management, from preclinical to post-approval stages, and he is adept at engaging with global

regulatory authorities and HTA/Payer bodies. This experience is complemented by his leadership within Patient Advocacy Group initiatives, fostering collaborations that ensure alignment with the needs of diverse Patient communities.

In senior executive roles, including his most recent as Chief Therapeutics Officer & Head of Medical and Scientific Affairs at Stratus Therapeutics and previous CMO appointments, Dr. Theocharous has demonstrated a strategic approach to business growth and commercialisation. His board-level expertise and collaboration with CEOs have added depth and credibility in interactions with

investors, venture capital, and banking partners. A co-founder of a London-based Biotech, Dr. Theocharous has not only built this venture from the ground up but has consistently steered strategic development and commercialisation efforts in a rapidly evolving Biotech landscape. Recently awarded the 2025 CYDIA Health Award for impact in healthcare and the Cypriot diaspora, and now CEO at VectorGen: advancing next-gen lentiviral vector platforms aimed at precision curative therapies, notably for HIV and inherited

monogenic pathologies.